Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment
Key facts
- Who runs it
- Capital Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 380 people enrolled
- Started
- 1 Nov 2024
- Ended
- 1 Jun 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)
- Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)
- Starch Placebo
- Record updated
- 30 October 2026
Who can take part
- Age
- 50 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged 50 to 70 years old
- Derived from the established elderly chronic disease and health cohort
- Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) (e.g., indicated by specific cut-off scores on the MoCA adjusted for education level)
- Volunteered to participate, able to cooperate with the cognitive assessments, and signed the informed consent form
Who cannot take part
- Current use or use within the past 3 months of cognition-improving drugs, Vitamin D, or Folic Acid supplements, and unwilling to undergo a 3-month washout period prior to the intervention
- Diagnosis of Alzheimer's disease, other types of dementia, or severe psychiatric disorders (e.g., severe depression, schizophrenia)
- History of severe neurological diseases (e.g., stroke, brain tumor, brain trauma) that may affect cognitive function
- Patients with liver diseases (e.g., hepatitis, liver cirrhosis) or kidney diseases (e.g., nephritis, kidney stones, renal failure)
- Patients with hypercalcemia (serum calcium concentration > 10.5 mg/dl)
- Severe visual or hearing impairments that prevent the completion of cognitive tests
- Patients with severe anemia, severe malnutrition, or abnormal thyroid function
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to investigate the effects of Vitamin D3 combined with Folic Acid on mild cognitive impairment (MCI). Participants aged 50 to 70 years with MCI will be randomly assigned to three groups: a low-dose Vitamin D3 plus Folic Acid group, a high-dose Vitamin D3 plus Folic Acid group, and a placebo group. The intervention will last for 6 months. The main goal is to observe whether this nutritional intervention can improve or delay the decline of cognitive function.
The 3 groups in the trial
- 800IU/d Vitamin D3 + Folic AcidTreatment being tested
Participants will receive one folic acid(0.4mg/d) tablet and one low-dose(800IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.
Treatment: Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)
- 1600IU/d Vitamin D3 + Folic AcidTreatment being tested
Participants will receive one folic acid(0.4mg/d) tablet and one high-dose(1600IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.
Treatment: Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)
- PlaceboPlacebo, for comparison
Participants will receive two starch placebo tablets (identical in appearance, color, and smell to the active supplements) orally once daily at breakfast for 6 months.
Treatment: Starch Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects and Mechanisms of Vitamin D Combined With Folic Acid and Vitamin B12 on Mild Cognitive Impairment Via Regulation of Key Factors in 27-Hydroxycholesterol Metabolism
- Record updated
- 30 October 2026